Soraya Allas

Ecully, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

A Randomized First-in-human Study of a Novel Growth Hormone Receptor Peptide Antagonist ALXN2420 in Healthy Subjects.

A Randomized First-in-human Study of a Novel Growth Hormone Receptor Peptide Antagonist ALXN2420 in Healthy Subjects.

Journal: European journal of endocrinology

Published: April 28, 2026

Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist.

Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist.

Journal: Endocrine connections

Published: September 12, 2024

An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism.

An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism.

Journal: The Journal of clinical endocrinology and metabolism

Published: November 03, 2023

Economic burden of patients with post-surgical chronic and transient hypoparathyroidism in the United States examined using insurance claims data.

Economic burden of patients with post-surgical chronic and transient hypoparathyroidism in the United States examined using insurance claims data.

Journal: Orphanet journal of rare diseases

Published: September 19, 2023

AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.

AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.

Journal: PloS one

Published: August 01, 2017

Unacylated ghrelin analog prevents myocardial reperfusion injury independently of permeability transition pore.

Unacylated ghrelin analog prevents myocardial reperfusion injury independently of permeability transition pore.

Journal: Basic research in cardiology

Published: April 20, 2016

Acylated and unacylated ghrelin during OGTT in Prader-Willi syndrome: a rebuttal to the conclusions by Kuppens et al.

Acylated and unacylated ghrelin during OGTT in Prader-Willi syndrome: a rebuttal to the conclusions by Kuppens et al.

Journal: Clinical endocrinology

Published: April 03, 2016

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes.

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes.

Journal: Diabetes, obesity & metabolism

Published: February 12, 2016

Response to inquiry by Gaylinn et al. on 'Administration of UAG improves glycemic control in obese subjects with diabetes'.

Response to inquiry by Gaylinn et al. on 'Administration of UAG improves glycemic control in obese subjects with diabetes'.

Journal: European journal of endocrinology

Published: June 01, 2015

Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader-Willi syndrome.

Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader-Willi syndrome.

Journal: Endocrine

Published: January 16, 2015

Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines.

Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines.

Journal: Scientific reports

Published: October 08, 2014

Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.

Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.

Journal: Investigational new drugs

Published: January 21, 2014

Showing 1-12 of 15

Last Updated: 09/26/2026